2021 annual meeting postponed to February 2022

By | Meetings, Webinar | No Comments

The IGG Committee have taken the decision to postpone our 2021 annual meeting to February 2022, and also to make it a virtual meeting.  This is due to a number of factors including uncertainty around government restrictions, attendee safety, company travel policies, and travel budget restrictions.

The precise date and timings are still to be confirmed but we will update you and share the agenda as soon as we are able.  The meeting will still include the Richard Williams award so we would like to invite all eligible speakers to stand for this (details with the revised entry deadline will be sent out soon).

Many thanks.

New Investigators HalloweeN! online event

By | Webinar | No Comments

We hope you’re looking forward to the EEMGS New Investigators’ HalloweeN! event next Thursday, 28th October, 6.30pm CET!

First we will gain tips and tricks for academic writing from Dr TJ Moore, followed by a chance to get to know each other at our GeNIus Pub Quiz.

To find more details on the event and to register please follow the link!

Join us if you dare, we’re looking forward to seeing you there!

P.s. Costumes are not compulsory but more than welcome!


Duplex Sequencing Webinar

By | Webinar | No Comments

Working from home? Keep up to date with the latest sequencing technology for mutation detection by joining a webinar on Thursday March 26th on Duplex Sequencing. To register, click here.

Title: Duplex Sequencing™ Technology: Transforming Safety Testing

Date: Thursday, March 26, 2020

Time: 11:00 AM Eastern Daylight Time

Duration: 1 hour


Bob Young, MS
Program Consultant and Study Director, In Vivo Mutation
Merck KGaA, Darmstadt, Germany

Jesse Salk, MD, PhD
CEL, CSO and Founder
TwinStrand Biosciences

In this webinar, you will learn about:

  • Duplex Sequencing™ technology unmatched sensitivity and accuracy in NGS applications
  • Duplex technology applications in identification of carcinogenic chemicals
  • Global efforts to evaluate and adopt Duplex Sequencing™ technology for regulatory submission
  • Applications in drug and chemical safety assessment

Detailed description:

Duplex Sequencing™ technology is a new error-corrected NGS method that improves sequencing accuracy 100,000-fold. This increase in accuracy opens the door to significant reductions in time spent in drug development, allowing measurement of a compound’s carcinogenic risk months or even years earlier than current methods. DS technology now permits early measurement of ultra-rare new mutants. We will discuss the technology, clinical applications and then explore nonclinical safety assessment applications. Mouse and rat mutation data will be presented from various mutagens, tissues and genes. Mutant frequency data and mutational “fingerprint” data will be discussed in context of human tumors. Plans for collaborative qualification through the HESI Genetic Toxicology Technical Committee will be discussed.